Familial lipoprotein lipase deficiency
MONDO:0009387Familial lipoprotein lipase deficiency is a rare genetic disorder is which a person lacks the enzyme lipoprotein lipase, a protein needed to break down fat molecules. Deficiency of this enzyme prevents affected individuals from properly digesting certain fats. This results in the accumulation of fatty droplets called chylomicrons in the blood and an increase in the blood concentration of triglycerides. Symptoms include episodes of abdominal pain, recurrent inflammation of the pancreas (pancreatitis), abnormal enlargement of the liver and/or spleen (hepatosplenomegaly), and the development of skin lesions known as erruptive xanthomas. Familial lipoprotein lipase deficiency is caused by changes (mutations) in the LPL gene. It is inherited in an autosomal recessive pattern. Treatment aims to control symptoms and blood triglyceride levels with a very low-fat diet. Treatment for individual symptoms (i.e. pancreatitis) involves following established treatment guidelines.
Also known as: familial chylomicronemia syndrome, hyperlipoproteinemia type I, hyperlipoproteinemia, type 1, hyperlipoproteinemia, type I, type I hyperlipoproteinemia, LPL deficiency, familial lipoprotein lipase deficiency (disorder) [ambiguous], familial lipoprotein lipase deficiency with type I phenotype
7 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can a Fat-Blocking pill tame deadly high blood fats?
Disease control Recruiting nowThis study tests whether orlistat, a drug that blocks fat absorption, can safely lower very high blood triglycerides in people with type 1 hyperlipoproteinemia, a rare genetic disorder. About 28 participants aged 8 and older will take orlistat or a placebo for several months. The…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug offers hope for rare, severe high triglyceride conditions
Disease control AVAILABLEThis program gives adults and adolescents with familial chylomicronemia syndrome (FCS) and adults with severe hypertriglyceridemia (SHTG) access to an experimental drug called plozasiran. Participants receive injections every 3 months for 15 to 21 months. The goal is to lower dan…
Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene-Editing shot aims to tame deadly fat levels in kids
Disease control Recruiting nowThis early-stage trial tests a new gene-editing treatment called CS-121 in 15 children and teens (ages 4-18) with a rare condition causing extremely high triglycerides. The therapy uses lipid nanoparticles to deliver a base editor that targets the APOC3 gene in the liver. The mai…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Scientists probe fat mystery in rare disease to pave way for new drugs
Knowledge-focused Recruiting nowThis study looks at how people with lipoprotein lipase (LPL) deficiency, a rare condition that causes extremely high blood fat levels, handle dietary fats. Researchers will use special imaging and breath tests to see where fat goes in the body and how it's used for energy. The go…
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC